Salvarx Group Share Price (SALV)

15.00 -2.50 (-14.29%) delayed: 5:52PM GMT
Bid price 10.00 Open price 16.20
Ask price 20.00 Prev close 15.00
High price 17.40 Spread 50.00%
Low price 11.00 Volume 56,814

Register now for FREE live Salvarx Group share prices, Salvarx Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Salvarx Group Level 2 Data, indepth research tools and investor commentary for Salvarx Group (SALV) and other London Stock Exchange equities.

Salvarx Group Share Price Chart

Advanced Charts >>

Register now for FREE Salvarx Group share price charts

Salvarx Group Share Price Information

Name Salvarx Group Epic SALV
Sector Health Care Equipment & Services ISIN IM00BZ4SS228
Activites SalvaRx Group plc (formerly 3Legs Resources plc) was founded in 2014 to develop therapies within the rapidly growing immuno-oncology market, which uses treatments designed to boost the body's natural defences to fight the cancer. Immuno-oncology therapy is a fast growing and new therapeutic area, a market expected to grow to $80 billion worldwide by 2020 (Global & USA Cancer Immunotherapy Market Analysis 2020). SalvaRx's strategy is to invest in a portfolio of companies involved in novel cancer immunotherapies and develop them up to clinical proof of concept. SalvaRx provides portfolio companies with operational support in addition to capital, either by managing its portfolio companies directly or augmenting an existing team. SalvaRx's management team have a proven track record of discovering and commercialising drugs in the area of cancer immunotherapy with Bristol-Myers Squibb and Johnson & Johnson. The team is supported by an extended network of senior academic and industry executives to promote commercial and scientific outcomes, including licensing and partnering discussions. Index n/a

Salvarx Group Key Numbers

Latest Share Price (p) 15.00 Net Gearing (%) 70.50
Market Capitalisation (£m) 6.42 Gross Gearing (%) 81.44
Shares in issue (m) 36.70 Debt Ratio 76.44
P/E Ratio -350.00 Debt-to-Equity Ratio 0.74
Total dividends per share (p) 0.00 Assets / Equity Ratio 5.39
Dividend Yield (%) 0.00 Price to book value 6.62
Dividend cover (x) 0.00 ROCE (%) -68.54
Earning per share (p) -0.05 EPS Growth (%) 16.67
52 week high / low 93.00 / 12.50 DPS Growth (%) n/a

Salvarx Group Director Deals

Dec.Date Type Director Pos No. of Shares
06/11/2018 EXR Jim Mellon CH 86,230
06/11/2018 EXR Greg Bailey NED 86,230

More Salvarx Group Director Deals >>

Salvarx Group Company News

07:00 31/01/2019

Change of Nominated Adviser and Broker

RNS Number : 5979O SalvaRx Group plc 31 January 2019   SalvaRx Group plc ("SalvaRx" or the "Company") Change of Nominated Adviser and Broker SalvaRx (AIM: SALV), the drug discovery and development company focused on cancer immunotherapy, announces that pursuant to...

14:05 17/01/2019

Second Price Monitoring Extn

RNS Number : 4189N SalvaRx Group plc 17 January 2019   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first...

14:00 17/01/2019

Price Monitoring Extension

RNS Number : 4188N SalvaRx Group plc 17 January 2019   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the...

More Salvarx Group Company News >>

Register now for FREE Salvarx Group company news

Salvarx Group Share Price Discussions

No Salvarx Group Share Price Discussions

Register now for FREE Salvarx Group share price discussions